Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurodegenerative disease characterized
by the degeneration of motor neurons in the brain and spinal cord. The disease leads to muscle
weakness, paralysis, and ultimately death, usually from respiratory failure. Although the exact cause
dysfunction, and neuroinflammation has been implicated. This essay delves into the pathophysiology,
clinical presentation, diagnostic approaches, current treatments, and emerging research in ALS, offering
an in-depth understanding of the disorder's complexity and ongoing efforts to manage and cure it.
1. Introduction
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative
disorder that affects the upper and lower motor neurons. It results in the progressive loss of voluntary
muscle control, leading to paralysis and eventual death. ALS affects approximately 2 per 100,000
individuals globally, with a median survival of three to five years post-diagnosis (Brown & Al-Chalabi,
2017). Despite decades of research, effective treatments remain limited, and the disease continues to
challenge clinicians and researchers alike. Understanding ALS's pathogenesis is essential to develop
2. Historical Background
ALS was first described in 1869 by French neurologist Jean-Martin Charcot. However, it gained public
attention in the United States when baseball player Lou Gehrig was diagnosed in 1939. Since then,
advances in genetics, imaging, and molecular biology have significantly improved our understanding of
ALS affects both upper motor neurons (located in the motor cortex) and lower motor neurons (in the
brainstem and spinal cord). The degeneration leads to symptoms such as spasticity, muscle wasting, and
fasciculations.
Approximately 10% of ALS cases are familial (fALS), with several gene mutations identified, including:
SOD1 (superoxide dismutase 1): The first gene linked to ALS, responsible for detoxifying
superoxide radicals.
C9orf72: The most common mutation in familial and some sporadic cases.
These mutations often lead to protein aggregation, disrupted cellular trafficking, and impaired RNA
Oxidative stress plays a significant role in ALS pathology. Reactive oxygen species (ROS) damage cellular
proteins, lipids, and DNA. Mitochondrial abnormalities also contribute by disrupting ATP production and
Excessive glutamate activity leads to overactivation of NMDA receptors and calcium influx, causing
neuronal injury. Impaired glutamate reuptake due to astrocytic dysfunction exacerbates the problem
3.5. Neuroinflammation
Microglia and astrocytes become activated in ALS, releasing pro-inflammatory cytokines such as TNF-α
and IL-1β. While initially protective, chronic inflammation can further damage motor neurons (Philips &
Robberecht, 2011).
4. Clinical Features
ALS usually presents between ages 40 and 70, with limb-onset (muscle weakness in arms or legs) being
most common. Bulbar-onset (affecting speech and swallowing) occurs in about 25% of cases.
4.2. Symptoms
Respiratory insufficiency
Despite motor neuron involvement, cognitive functions are typically preserved, although a subset
5. Diagnosis of ALS
These diagnostic criteria require evidence of both upper and lower motor neuron degeneration in
neuropathies.
MRI is used to exclude structural lesions. Research into biomarkers such as neurofilament light chain
Patients benefit significantly from care involving neurologists, physiotherapists, speech therapists,
Antisense oligonucleotides (ASOs) targeting SOD1 and C9orf72 mutations show promise in preclinical
inflammation.
Trials involving drugs like masitinib (a tyrosine kinase inhibitor) are ongoing.
Genomic profiling and biomarker-driven trials may lead to tailored therapies in the future.
ALS remains incurable, with a median survival of 3–5 years. However, multidisciplinary care, respiratory
support, and symptomatic management can improve survival and quality of life. Some individuals, like
physicist Stephen Hawking, have lived for decades with the disease, highlighting variability in
progression.
ALS poses profound ethical challenges related to autonomy, end-of-life care, and access to experimental
treatments. Counseling, advanced care planning, and support for caregivers are essential components of
holistic care.
10. Conclusion
pathophysiology involving genetic, molecular, and cellular mechanisms. While current treatments offer
modest benefits, ongoing research provides hope for breakthroughs. A deeper understanding of ALS's
underlying biology and a commitment to translational research are essential to finding effective
Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. The New England Journal of
Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., ... & Yamashita, T.
(2020). Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal
Philips, T., & Robberecht, W. (2011). Neuroinflammation in amyotrophic lateral sclerosis: role of
glial activation in motor neuron disease. The Lancet Neurology, 10(3), 253-263.
Smith, E. F., Shaw, P. J., & De Vos, K. J. (2019). The role of mitochondria in amyotrophic lateral
Steinacker, P., Hendrich, C., Sperfeld, A. D., Jesse, S., von Arnim, C. A., Lehnert, S., ... & Otto, M.
(2016). Neurofilament as a blood marker for diagnosis and monitoring of ALS. Frontiers in
Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., McLaughlin, P., Snowden, J., ... &
Taylor, J. P., Brown Jr, R. H., & Cleveland, D. W. (2016). Decoding ALS: from genes to mechanism.
Van Damme, P., Van Den Bosch, L., & Robberecht, W. (2017). Excitotoxicity and amyotrophic